Biotech ETFs Surge After Eli Lilly Buys Out Loxo Oncology
Biotechnology stocks and sector-related ETFs were among the best performers Monday after Eli Lilly (NYSE: LLY) said it will acquire…
SBIO
ALPS Medical Breakthroughs ETF
$33.92 +$0.67
(+2.02%)
As of 1:00:00 AM EDT | 2/15/19 | Market Closed
SBIO Trading Data
Open
$33.45
Low Price
$33.31
High Price
$33.94
Previous Last Price
$33.25
Bid Size
$0 X 0
Ask Size
$0 X 0
SBIO Portfolio Data
AUM
$181,665,000
Shares
5,500
PE Ratio
12.55
Price / Book Ratio
3.39
Expense Ratio
0.5
Net Asset Value
$33.03
Volume
Volume
37,300
Avg. Volume (YDT)
46,434
Dollar Volume
$1,125,662
Weekly Avg. Volume
31,160
Monthly Avg. Volume
50,055
Quarterly Avg. Volume
75,893
SBIO Fund Description
The ALPS Medical Breakthroughs ETF invests in the public equity markets of the United States. It invests in the stocks of companies operating in the biotechnology and pharmaceutical sectors. The fund invests in stocks of mid cap and small cap companies with a market capitalization of no less than $200 million and no more than $5 billion. It seeks to replicate the performance of the Poliwogg Medical Breakthroughs Index, by investing in the stocks of companies as per their weightings in the index.
SBIO Chart
SBIO Summary
Fund Family
ALPS Holdings
Tracks This Index
ALPS Medical Breakthroughs ETF
Inception Date
2015-01-05
Asset Class
Portfolio-Multi Asset
Asset Class Size
Healthcare
SBIO Classification
Region (General)
Global
Region (Specific)
Sector
Health Care
Equity Index
Leveraged Family
SBIO Holdings
Top 10 Holdings
Cash and Equivalents
674%
FibroGen Inc. (FGEN)
581%
Array BioPharma Inc. (ARRY)
576%
United Therapeutics Corp. (UTHR)
444%
Agios Pharmaceuticals Inc. (AGIO)
403%
Galapagos NV (GLPG)
397%
Emergent BioSolutions Inc. (EBS)
394%
Ascendis Pharma AS (ASND)
361%
Global Blood Therapeutics Inc. (GBT)
338%
Immunomedics Inc. (IMMU)
305%
Total SBIO Holdings
Total Holdings: 72
Cash and Equivalents
674%
FibroGen Inc. (FGEN)
581%
Array BioPharma Inc. (ARRY)
576%
United Therapeutics Corp. (UTHR)
444%
Agios Pharmaceuticals Inc. (AGIO)
403%
Galapagos NV (GLPG)
397%
Emergent BioSolutions Inc. (EBS)
394%
Ascendis Pharma AS (ASND)
361%
Global Blood Therapeutics Inc. (GBT)
338%
Immunomedics Inc. (IMMU)
305%
Ligand Pharmaceuticals Inc. (LGND)
301%
Arena Pharmaceuticals Inc. (ARNA)
288%
Halozyme Therapeutics Inc. (HALO)
288%
Mirati Therapeutics Inc. (MRTX)
276%
Insmed Inc. (INSM)
244%
Madrigal Pharmaceuticals Inc. (MDGL)
243%
Enanta Pharmaceuticals Inc. (ENTA)
234%
Acceleron Pharma Inc. (XLRN)
230%
Atara Biotherapeutics Inc. (ATRA)
216%
AnaptysBio Inc. (ANAB)
214%
CRISPR Therapeutics AG (CRSP)
189%
PTC Therapeutics Inc. (PTCT)
175%
uniQure NV (QURE)
162%
Rhythm Pharmaceuticals Inc. (RYTM)
121%
Fate Therapeutics Inc. (FATE)
112%
MacroGenics Inc. (MGNX)
107%
Vericel Corp. (VCEL)
98%
ImmunoGen Inc. (IMGN)
98%
G1 Therapeutics Inc. (GTHX)
91%
Apellis Pharmaceuticals Inc. (APLS)
91%
Acorda Therapeutics Inc. (ACOR)
79%
Cara Therapeutics Inc. (CARA)
78%
UroGen Pharma Ltd. (URGN)
77%
Viking Therapeutics Inc. (VKTX)
75%
Akebia Therapeutics Inc. (AKBA)
74%
AMAG Pharmaceuticals Inc. (AMAG)
67%
Kura Oncology Inc. (KURA)
66%
Flexion Therapeutics Inc. (FLXN)
65%
ChemoCentryx Inc. (CCXI)
64%
GlycoMimetics Inc. (GLYC)
60%
Corbus Pharmaceuticals Holdings Inc. (CRBP)
60%
PDL BioPharma Inc. (PDLI)
57%
Progenics Pharmaceuticals Inc. (PGNX)
48%
Five Prime Therapeutics Inc. (FPRX)
48%
NuCana PLC (NCNA)
43%
ArQule Inc. (ARQL)
43%
Concert Pharmaceuticals Inc. (CNCE)
41%
Voyager Therapeutics Inc. (VYGR)
41%
CASI Pharmaceuticals Inc. (CASI)
40%
Krystal Biotech Inc. (KRYS)
39%
Achillion Pharmaceuticals Inc. (ACHN)
38%
Aduro Biotech Inc. (ADRO)
37%
MediciNova Inc. (MNOV)
37%
Abeona Therapeutics Inc. (ABEO)
37%
Albireo Pharma Inc. (ALBO)
37%
Minerva Neurosciences Inc. (NERV)
35%
Adamas Pharmaceuticals Inc. (ADMS)
33%
Catalyst Pharmaceuticals Inc. (CPRX)
33%
Kiniksa Pharmaceuticals Ltd. (KNSA)
32%
AC Immune SA (ACIU)
31%
Savara Inc. (SVRA)
28%
Synlogic Inc. (SYBX)
28%
Syros Pharmaceuticals Inc. (SYRS)
27%
Tocagen Inc. (TOCA)
25%
Athersys Inc. (ATHX)
25%
MEI Pharma Inc. (MEIP)
25%
Arbutus Biopharma Corp. (ABUS)
25%
Calithera Biosciences Inc. (CALA)
24%
Xenon Pharmaceuticals Inc. (XENE)
24%
State Street Institutional Treasury Plus Money Market Fund (TPIXX)
3%
ALPS Medical Breakthroughs ETF (SBIO)
0%
Corium International Inc (CORI-CVR)
0%
SBIO Technicals
Alpha
-8.64
Beta
1.69
Leverage
Long
Standard Deviation
3.01
SBIO Dividends
Dividend Date
2018-12-20
Latest Dividend
0.784
Annual Dividend
0.78
Annual Dividend Rate
0.78
Annual Dividend Yield
2.37
SBIO Performance
YTD Return
20.54%
1 Year Return
-5.17%
3 Year Return
51.7%
5 Year Return
0%
10 Year Return
36.55%
SBIO Related Articles
6 Top Healthcare ETFs Rally as Trump Vows End to ‘Global Freeloading’
Healthcare stocks and top healthcare ETFs rallied Friday after President Donald Trump vowed to end to “global freeloading” that has…
A Nifty Biotech ETF Idea for 2018
Biotechnology stocks bolstered the broader healthcare sector last year, a theme that is expected to continue in 2018. Investors looking…
Biotech ETFs Jump on Gilead, Kite Deal
The biotechnology segment rallied Monday with small-cap biotech names and related exchange traded funds leading the charge after Gilead Sciences…
ETF Performance Report: February 2017
U.S. equities and stock exchange traded funds ended February on a sullen note, with the Dow Jones Industrial Average snapping…
Healthcare ETFs Are Latest Victim to Trump
Healthcare stocks, especially the biotech segment, and related exchange traded funds plunged Wednesday after President-elect Donald Trump singled out the…